Laparoscopic Sleeve Gastrectomy: Bariatric Surgery Peak?
Main Article Content
Abstract
Bariatric surgery is a great option not only for rapid weight loss but also as an alternative for type 2 diabetes mellitus and ravages of metabolic syndrome. The Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently showed that this surgical alternative is better than the more aggressive treatment against diabetes and the ravages of metabolic syndrome.
The laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric operation. Weight loss is achieved by drastically reducing the capacity of the gastric chamber, consequently, making the patient undergoing this procedure reduce their food consumption. In addition to this, the presence of biochemical changes lead the patient to a state of significant weight loss, with ghrelin being the main hormone involvedVarious authors conclude that sleeve gastrectomy is "the holy grail of bariatric surgery", but it is not. If so, this was the only surgery performed by these surgeons, which is not the case. Its benefits on the control of obesity as well as the almost complete remission of type 2 diabetes mellitus are very clear. Its intention is a surgery without the need for anastomosis and with preservation of the digestive tract, which makes it of very low mortality as well as future complications, including the few nutritional deficiencies that patients present after the procedure. In conclusion, laparoscopic sleeve gastrectomy deserves an important place among the bariatric procedures performed.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mattar S, Velcu L, Schauer P. Surgically-induced weight loss significantly improves nonalcholoic fatty liver disease and the metabolic syndrome. Ann Surg. 2005;242(4):610–7.
II. Schauer P, Bhatt DL, Kirwan JP. Bariatric surgery versus intensive medical therapy for diabetes- 3 year outcomes. N Engl J Med. 2014;370(21):2002–13.
III. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg [Internet]. 1979;66(9):618–20. Disponible en: http://dx.doi.org/10.1002/bjs.1800660906
IV. Lagacé M, Marceau P, Marceau S, Hould FS, Potvin M, Bourque RA, et al. Biliopancreatic diversion with a new type of gastrectomy: Some previous conclusions revisited. Obes Surg [Internet]. 1995;5(4):411–8. Disponible en:
http://dx.doi.org/10.1381/096089295765557511
V. Rosenthal RJ, International Sleeve Gastrectomy Expert Panel, Diaz AA, Arvidsson D, Baker RS, Basso N, et al. International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis [Internet]. 2012;8(1):8–19. Disponible en:
http://dx.doi.org/10.1016/j.soard.2011.10.019
VI. Vidal J, Ibarzabal A, Romero F, Delgado S, Momblán D, Flores L, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg [Internet]. 2008;18(9):1077–82. Disponible en: http://dx.doi.org/10.1007/s11695-008-9547-2
VII. Nocca D. Laparoscopic adjustable gastric banding and laparoscopic sleeve gastrectomy: which has a place in the treatment of diabetes in morbidly obese patients? Diabetes Metab [Internet]. 2009;35(6 Pt 2):524–7. Disponible en:
http://dx.doi.org/10.1016/S1262-3636(09)73460-3
VIII. Nocca D, Guillaume F, Noel P, Picot MC, Aggarwal R, El Kamel M, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg [Internet]. 2011;21(6):738–43. Disponible en:
http://dx.doi.org/10.1007/s11695-011-0385-2
IX. Cutolo PP, Nosso G, Vitolo G, Brancato V, Capaldo B, Angrisani L. Clinical efficacy of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass in obese type 2 diabetic patients: a retrospective comparison. Obes Surg [Internet]. 2012;22(10):1535–9. Disponible en:
http://dx.doi.org/10.1007/s11695-012-0657-5
X. Sarela AI, Dexter SPL, O’Kane M, Menon A, McMahon MJ. Long-term follow-up after laparoscopic sleeve gastrectomy: 8-9-year results. Surg Obes Relat Dis [Internet]. 2012;8(6):679–84. Disponible en:
http://dx.doi.org/10.1016/j.soard.2011.06.020
XI. Johnston D, Dachtler J, Sue-Ling HM, King RFGJ, Martin LG. The Magenstrasse and Mill operation for morbid obesity. Obes Surg [Internet]. 2003;13(1):10–6. Disponible en: http://dx.doi.org/10.1381/096089203321136520
XII. Gagner M, Deitel M, Erickson AL, Crosby RD. Survey on laparoscopic sleeve gastrectomy (LSG) at the Fourth International Consensus Summit on Sleeve Gastrectomy. Obes Surg [Internet]. 2013;23(12):2013–7. Disponible en:
http://dx.doi.org/10.1007/s11695-013-1040-x
XIII. Gill RS, Birch DW, Shi X, Sharma AM, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: A systematic review. Can J Diabetes [Internet]. 2011;35(2):150. Disponible en:
http://dx.doi.org/10.1016/s1499-2671(11)52050-7
XIV. Trastulli S, Desiderio J, Guarino S, Cirocchi R, Scalercio V, Noya G, et al. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg Obes Relat Dis [Internet]. 2013; 9(5):816–29. Disponible en: http://dx.doi.org/10.1016/j.soard.2013.05.007
XV. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg [Internet]. 2013;23(4):427–36. Disponible en:
http://dx.doi.org/10.1007/s11695-012-0864-0
XVI. Kraljević M, Cordasco V, Schneider R, Peters T, Slawik M, Wölnerhanssen B, et al. Correction to: Long-term effects of laparoscopic sleeve gastrectomy: What are the results beyond 10 years? Obes Surg [Internet]. 2021;31(8):3434–5. Disponible en: http://dx.doi.org/10.1007/s11695-021-05460-4
XVII. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study: A prospective, double blind study. Ann Surg [Internet]. 2008;247(3):401–7. Disponible en: http://dx.doi.org/10.1097/SLA.0b013e318156f012
XVIII. Dogan U, Bulbuller N, Cakır T, Habibi M, Mayir B, Koc U, et al. Nesfatin-1 hormone levels in morbidly obese patients after laparoscopic sleeve gastrectomy. Eur Rev Med Pharmacol Sci. 2016;20(6):1023–31.
XIX. Dempsey DT. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. year b dig dis [Internet]. 2007;2007:196–8. Disponible en: http://dx.doi.org/10.1016/s0739-5930(08) 70162-4
XX. Tucker ON, Szomstein S, Rosenthal RJ. Indications for sleeve gastrectomy as a primary procedure for weight loss in the morbidly obese. J Gastrointest Surg [Internet]. 2008;12(4):662–7. Disponible en: http://dx.doi.org/10.1007/s11605-008-0480-4